147 related articles for article (PubMed ID: 38206595)
1. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.
Bischoff LA; Ganly I; Fugazzola L; Buczek E; Faquin WC; Haugen BR; McIver B; McMullen CP; Newbold K; Rocke DJ; Russell MD; Ryder M; Sadow PM; Sherman E; Shindo M; Shonka DC; Singer MC; Stack BC; Wirth LJ; Wong RJ; Randolph GW
JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):265-272. PubMed ID: 38206595
[TBL] [Abstract][Full Text] [Related]
2. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
3. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
4. Significance of oncocytic features in poorly differentiated thyroid carcinoma - a bi-institutional experience.
Xu B; Lubin DJ; Dogan S; Ghossein RA; Viswanathan K
Virchows Arch; 2023 Mar; 482(3):479-491. PubMed ID: 36346459
[TBL] [Abstract][Full Text] [Related]
5. The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile.
Metovic J; Vignale C; Annaratone L; Osella-Abate S; Maletta F; Rapa I; Cabutti F; Patriarca S; Gallo M; Nikiforov YE; Volante M; Papotti M
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32936917
[TBL] [Abstract][Full Text] [Related]
6. Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features.
Xu B; Reznik E; Tuttle RM; Knauf J; Fagin JA; Katabi N; Dogan S; Aleynick N; Seshan V; Middha S; Enepekides D; Casadei GP; Solaroli E; Tallini G; Ghossein R; Ganly I
Endocrine; 2019 Apr; 64(1):97-108. PubMed ID: 30689169
[TBL] [Abstract][Full Text] [Related]
7. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
[TBL] [Abstract][Full Text] [Related]
8. Poorly differentiated oncocytic (hürthle cell) follicular carcinoma: an institutional experience.
Bai S; Baloch ZW; Samulski TD; Montone KT; LiVolsi VA
Endocr Pathol; 2015 May; 26(2):164-9. PubMed ID: 25898815
[TBL] [Abstract][Full Text] [Related]
9. Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach.
Jung CK; Bychkov A; Kakudo K
Endocrinol Metab (Seoul); 2022 Oct; 37(5):703-718. PubMed ID: 36193717
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma.
Wenter V; Albert NL; Unterrainer M; Ahmaddy F; Ilhan H; Jellinek A; Knösel T; Bartenstein P; Spitzweg C; Lehner S; Todica A
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):449-460. PubMed ID: 32683470
[TBL] [Abstract][Full Text] [Related]
11. Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance.
Sobrinho-Simões M; Máximo V; Castro IV; Fonseca E; Soares P; Garcia-Rostan G; Oliveira MC
Int J Surg Pathol; 2005 Jan; 13(1):29-35. PubMed ID: 15735852
[TBL] [Abstract][Full Text] [Related]
12. Short Review: Genomic Alterations in Hürthle Cell Carcinoma.
Ganly I; McFadden DG
Thyroid; 2019 Apr; 29(4):471-479. PubMed ID: 30848171
[TBL] [Abstract][Full Text] [Related]
13. PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma.
Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW
Endocr Pathol; 2015 Dec; 26(4):365-9. PubMed ID: 26530486
[TBL] [Abstract][Full Text] [Related]
14. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization.
Tallini G; Hsueh A; Liu S; Garcia-Rostan G; Speicher MR; Ward DC
Lab Invest; 1999 May; 79(5):547-55. PubMed ID: 10334566
[TBL] [Abstract][Full Text] [Related]
15. Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fine-needle aspirates diagnosed as follicular neoplasm of Hürthle cell (oncocytic) type.
Landau MS; Nikiforov YE; Ohori NP; Chiosea SI
Cancer Cytopathol; 2021 Oct; 129(10):788-797. PubMed ID: 33901345
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.
Xu B; Ghossein R
Eur J Surg Oncol; 2018 Mar; 44(3):338-347. PubMed ID: 28554832
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Hurthle cell thyroid carcinoma does not preclude long-term survival: a case report and review of the literature.
Blossey RD; Kleine-Döpke D; Ringe KI; Pöhnert D; Ringe B; Klempnauer J; Beetz O
J Med Case Rep; 2021 Aug; 15(1):399. PubMed ID: 34376229
[TBL] [Abstract][Full Text] [Related]
18. Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid.
Máximo V; Preto A; Crespo A; Rocha AS; Machado JC; Soares P; Sobrinho-Simões M
BMC Cancer; 2004 Mar; 4():12. PubMed ID: 15043758
[TBL] [Abstract][Full Text] [Related]
19. Well-differentiated carcinoma of the thyroid.
Boone RT; Fan CY; Hanna EY
Otolaryngol Clin North Am; 2003 Feb; 36(1):73-90, viii. PubMed ID: 12803010
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.
Ito Y; Miyauchi A
Endocr J; 2009; 56(2):177-92. PubMed ID: 18703852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
